Free Trial

Insider Selling: ReposiTrak Inc. (NYSE:TRAK) CEO Sells 3,500 Shares of Stock

ReposiTrak logo with Computer and Technology background

ReposiTrak Inc. (NYSE:TRAK - Get Free Report) CEO Randall K. Fields sold 3,500 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $18.27, for a total value of $63,945.00. Following the completion of the sale, the chief executive officer owned 132,000 shares in the company, valued at approximately $2,411,640. This represents a 2.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

ReposiTrak Stock Up 1.8%

ReposiTrak stock traded up $0.32 during midday trading on Friday, reaching $18.39. The company's stock had a trading volume of 25,814 shares, compared to its average volume of 50,029. ReposiTrak Inc. has a fifty-two week low of $15.72 and a fifty-two week high of $25.01. The company has a current ratio of 6.03, a quick ratio of 6.03 and a debt-to-equity ratio of 0.01. The stock has a market cap of $336.10 million, a P/E ratio of 54.09 and a beta of 0.51. The stock's 50-day moving average is $20.25.

ReposiTrak Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 14th. Shareholders of record on Monday, June 30th will be issued a dividend of $0.0182 per share. This represents a $0.07 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Monday, June 30th. ReposiTrak's payout ratio is 23.53%.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded ReposiTrak from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

Read Our Latest Research Report on ReposiTrak

Hedge Funds Weigh In On ReposiTrak

An institutional investor recently raised its position in ReposiTrak stock. Ellsworth Advisors LLC grew its position in shares of ReposiTrak Inc. (NYSE:TRAK - Free Report) by 10.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,289 shares of the company's stock after purchasing an additional 2,997 shares during the quarter. Ellsworth Advisors LLC owned approximately 0.17% of ReposiTrak worth $634,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 27.35% of the company's stock.

ReposiTrak Company Profile

(Get Free Report)

Park City Group, Inc, a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance and Food Safety solutions, which reduces potential regulatory and legal risk from their supply chain partners; and ReposiTrak Supply Chain solutions that enables customers to manage relationships with suppliers.

Further Reading

Insider Buying and Selling by Quarter for ReposiTrak (NYSE:TRAK)

Should You Invest $1,000 in ReposiTrak Right Now?

Before you consider ReposiTrak, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ReposiTrak wasn't on the list.

While ReposiTrak currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines